Triple-positive and triple-negative breast cancer refers to the expression of estradiol receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2). Expression of all three is considered triple-positive, and expression of none of the three is considered triple-negative. 1. Estradiol receptor (ER): Estradiol receptor is found in the nucleus of normal breast epithelial cells, where the hormone forms a dimer with the receptor to initiate the cell division cycle. Blocking the action of ER can inhibit the growth of breast cancer. 2. Progesterone receptor (PR): the significance of progesterone receptor is similar to that of estradiol receptor mentioned above. And for those who are positive for both ER and PR, endocrine therapy can be applied as an adjunct to breast cancer treatment. Secondly, ER and PR are also related to the prognosis of breast cancer, and those who are positive have low metastasis rate and long tumor-free survival time. 3. Epidermal growth factor receptor 2 (HER2): this receptor is also related to the prognosis of breast cancer, but contrary to the above, those with HER2 overexpression have high proliferative activity and poor prognosis. Molecular markers and molecular staging of breast cancer are important for guiding clinical treatment and judging prognosis. For the clinical treatment corresponding to specific molecular markers of breast cancer, it is recommended that patients consult with their specialists and actively cooperate with the treatment according to the doctor’s instructions.